Company / PP&E (Net)
Relay Therapeutics, Inc. PP&E (Net) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.7M
FY2025
5-year range
$1.7M / $11.6M
FY2021-FY2025
Trend
-70.8%
vs FY2024
Sector context
#139 of 193
Health Care
What the data says
At $2M, Relay Therapeutics, Inc.'s pp&e (net) ranks #139 of 193 in the Health Care sector. PP&E (Net) has declined for 3 consecutive years, from $12M in FY2022 to $2M in FY2025.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of -22.7%.
Declined from $11M to $2M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -47.1%
- 5-Year CAGR
- -22.7%
- 10-Year CAGR
- -
Sector benchmark
#139 of 193 in Health CareTop 72% of 193This company $1.7M Sector average $777.6M
▼
-99.8% below sector average
Key checks
Key Insights
- Relay Therapeutics, Inc.'s pp&e (net) has declined for 3 consecutive years.
- 5-year CAGR of -22.7%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 70.8% year-over-year.
- Ranks #139 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.7M | -70.8% |
| FY2024 | $5.9M | -45.8% |
| FY2023 | $10.9M | -6.3% |
| FY2022 | $11.6M | +77.8% |
| FY2021 | $6.5M | +4.7% |
| FY2020 | $6.3M | -22.8% |
| FY2019 | $8.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026